The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S. endocrinologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. The interaction between payers and physicians, including how reimbursement decisions impact prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in the second line following metformin monotherapy.


Related Reports

Type 2 Diabetes | Landscape & Forecast | Disease Landscape & Forecast

The type 2 diabetes therapy market will steadily expand over the 2018-2028 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the d...

View Details

Type 2 Diabetes | Unmet Need | Detailed, Expanded Analysis (US/EU)

The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging ther...

View Details

Type 2 Diabetes | Access & Reimbursement | Detailed, Expanded Analysis (US)

The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition between antidiabetic therapies, the type 2 diabetes access and r...

View Details

Type 2 Diabetes | Geographic Focus: China | Type 2 Diabetes | China In-Depth | China

Type 2 diabetes (T2D) is one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Traditional therapies such as...

View Details